Diligence memo · auto-generated · as of July 2, 2026
Oligomerix, Inc.
Oligomerix, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Oligomerix, Inc. operates in Pharmaceuticals, based in WHITE PLAINS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Oligomerix, Inc. has raised $8.3M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.8M on 2013-07-01.
Most recent recorded round closed around 2022-03-24.
Valuation (modeled)modeled
Provath models Oligomerix, Inc. at approximately $38M (range $1.8M–$186M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.93× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 39 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 6.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 51% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 37% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc., AION Healthspan, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.